15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Senti Biosciences Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $6.00 to $12.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $10.00 sits 2458% above the current $0.39. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.33 next quarter toward $-0.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Senti Biosciences Inc.
As of Aug, 3 of 3 firms rate SNTI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SNTI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.44 – $-0.21 · 2 analysts · -39% YoY
Next period, 2 analysts expect Senti Biosciences Inc to earn $-0.33 a share (range $-0.44 – $-0.21), versus $-0.53 a year earlier. Full-year consensus is $-1.04, growing to $-0.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $50.0K, rising to $50.0K next year.
Top analysts covering Senti Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNTI.
#1
Geulah Livshits
Chardan Capital · Rank #92
Buy
$12.00+2969.8% to target
Overall win rate
45%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #396
Buy
$12.00+2969.8% to target
Overall win rate
23%
+ Follow
#3
JL
Jeffrey La Rosa
Leerink Partners
Buy
No targeton SNTI
Coverage
—
+ Follow
#4
YJ
Yale Jen
Laidlaw & Co.
Buy
$15.00+3737.3% to target
Coverage
—
+ Follow
SNTI stock forecast FAQ
What is SNTI's average 12-month price target?+
The 3 analysts with a live target average $10.00 for Senti Biosciences Inc over the next 12 months, ranging from a $12.00 high to a $6.00 low.
Is SNTI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SNTI?+
The Street-high target is $12.00 (Chardan Capital), and the Street-low is $6.00 (Leerink Partners). The average of all 3 active targets is $10.00.
How many Wall Street analysts cover SNTI?+
3 analysts have an active rating on Senti Biosciences Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering SNTI?+
Among analysts who currently cover SNTI, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #92). Their current call is Buy with a $12.00 target.
What is Senti Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.44 – $-0.21) across 2 analysts. Full-year EPS is projected at $-1.04, rising to $-0.95 the following year.
How much revenue is Senti Biosciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $50.0K, growing to $50.0K next year.
Have analysts been upgrading or downgrading SNTI lately?+
As of Aug, 3 of 3 firms rate SNTI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNTI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
